Conclusions Selectively modulating the ‘context’ of glycolytic macrophages in HCC tumours might restore their antitumourigenic properties and provide a precise strategy for anticancer therapy.

Figure 4 PD-L1 expression and localization of macrophages in early and late stages of NSCLC. Tumor-associated macrophages express high levels of PD-L1 through activation of HIF1α, COX2 signaling, ...

Macrophages promote pancreatic cancer initiation, growth and metastasis. Depletion of MDSC or macrophage subsets results in increased infiltration and activation of CD8 + T cells. The programmed cell ...

If you have non-small cell lung cancer (NSCLC), your doctor will recommend PD-L1 testing. This test will help your doctor understand if you can be treated with a type of cancer drug called immune ...

New research highlights the potential of the novel diagnostic tool iFRET to determine immunotherapy outcomes in stage 2 ...

New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal ...

Chair of the Department of Cell, Developmental and Cancer Biology of the Knight Cancer Institute at the Oregon Health and ...

To characterize immune cells, the markers for CD3 (T-cells), FoxP3 (Regulatory T-cells), CD4 (Helper T-cells), CD8 (Cytotoxic T-cells), PD-L1 (Immune response co-inhibitory factors on tumor and ...

Explore how immune time-resolved Förster resonance energy transfer (iFRET) offers new insights into predicting immunotherapy ...

近日，来自复旦大学药学院陆伟教授、上海交通大学医学院肖泽宇教授该研究在 Nature Communications发表了题为 “CD133+PD-L1+ cancer cells confer resistance to adoptively transferred engineered macrophage-based therapy in ...